Definition and epidemiology
Cardiovascular disease (CVD) refers broadly to conditions affecting the heart and blood vessels, including coronary artery disease (CAD), cerebrovascular disease (stroke/TIA), peripheral artery disease (PAD), heart failure, and valvular disease. The dominant underlying process in adults is atherosclerosis, a chronic inflammatory disease of medium and large arteries.
CVD is the leading cause of death worldwide, responsible for roughly one-third of global mortality according to WHO estimates. Prevalence rises sharply with age, and men are affected earlier than women, though the gap narrows after menopause due to loss of estrogen's vascular protective effects.
- Low- and middle-income countries now bear a majority of the global CVD burden
- Incidence has declined in many high-income countries due to risk factor control, though obesity and diabetes trends threaten this progress
- CVD is not captured by a single ICD-10 code; it is coded by specific disease entity (e.g., I20-I25 for ischemic heart disease, I63 for ischemic stroke, I70 for atherosclerosis, I50 for heart failure)
- Atherosclerotic plaque rupture with thrombosis is the final common pathway for most acute cardiovascular events
- Foam cells (lipid-laden macrophages) form the earliest visible atherosclerotic lesion, the fatty streak
- Stable plaques cause predictable exertional symptoms; unstable plaques with thin caps cause acute events
- Statins and antiplatelets are foundational in both primary and secondary prevention
- ASCVD risk calculators integrate age, lipids, blood pressure, diabetes, and smoking to guide therapy
- SGLT2 inhibitors and GLP-1 agonists now have proven cardiovascular benefit beyond glycemic control
- Women and diabetics more often present with atypical symptoms (dyspnea, fatigue) rather than classic chest pain
- Family history of premature CVD is defined as a first-degree relative under 55 (men) or 65 (women)
Etiology and risk factors
CVD risk factors are divided into modifiable and non-modifiable categories.
Non-modifiable
- Age (risk rises progressively)
- Male sex (until menopause narrows the gap)
- Family history of premature CVD (first-degree relative, men under 55, women under 65)
- Genetic conditions, e.g., familial hypercholesterolemia
Modifiable
- Hypertension
- Dyslipidemia (elevated LDL, low HDL)
- Diabetes mellitus and insulin resistance
- Cigarette smoking
- Obesity and sedentary lifestyle
- Chronic kidney disease
- Poor diet (high sodium, saturated fat, low fiber)
- Chronic psychosocial stress
Validated risk calculators (e.g., ASCVD Pooled Cohort Equations, SCORE2 in Europe) combine these factors to estimate 10-year event risk and guide statin and antihypertensive decisions.
Pathophysiology
Atherosclerosis begins with endothelial injury or dysfunction, often from hypertension, hyperlipidemia, or smoking toxins. This allows LDL particles to infiltrate the subendothelial space, where they undergo oxidation and trigger an inflammatory response.
- Monocytes adhere to activated endothelium, migrate into the intima, and differentiate into macrophages
- Macrophages engulf oxidized LDL, becoming lipid-laden foam cells that form the fatty streak, the earliest visible lesion
- Smooth muscle cells migrate from the media and proliferate, producing a fibrous cap over a lipid-rich necrotic core
- Stable plaques have thick fibrous caps and narrow the lumen gradually, causing predictable exertional symptoms (stable angina, claudication)
- Unstable (vulnerable) plaques have thin caps and large lipid cores; cap rupture exposes thrombogenic material to the bloodstream, triggering platelet aggregation and thrombus formation
This rupture-thrombosis sequence underlies acute coronary syndromes, most ischemic strokes, and acute limb ischemia. In parallel, chronic pressure or volume overload (from hypertension, valvular disease, or ischemic injury) drives myocardial remodeling that leads to heart failure.
Clinical features
Presentation depends on the vascular bed involved.
| Territory | Typical presentation |
|---|---|
| Coronary | Exertional chest pain (stable angina) or rest pain (acute coronary syndrome), dyspnea |
| Cerebrovascular | Sudden focal neurologic deficit, transient ischemic attack |
| Peripheral | Intermittent claudication, rest pain, non-healing ulcers |
| Cardiac (heart failure) | Dyspnea, orthopnea, fatigue, peripheral edema |
- Many patients are asymptomatic for years while atherosclerosis progresses silently
- Risk factors (hypertension, obesity, smoking history) are often identified before symptomatic disease
- Atypical presentations (fatigue, dyspnea without chest pain) are more common in women, diabetics, and the elderly
Diagnosis
Diagnosis combines risk stratification, functional testing, and imaging depending on the suspected territory.
Initial workup
- Lipid panel, fasting glucose/HbA1c, blood pressure measurement
- ECG for ischemic changes or arrhythmia
- Calculation of 10-year ASCVD risk score
Targeted testing
- Stress testing (exercise or pharmacologic) for suspected stable CAD
- Coronary CT angiography or invasive coronary angiography for anatomic assessment
- Carotid duplex ultrasound or CT/MR angiography for cerebrovascular disease
- Ankle-brachial index for peripheral artery disease
- Echocardiography for structural and functional cardiac assessment
- Troponin and serial ECGs when acute coronary syndrome is suspected
Coronary artery calcium scoring can refine risk estimation in patients with intermediate calculated risk.
Differential diagnosis
- Non-cardiac chest pain: gastroesophageal reflux, musculoskeletal pain, panic disorder
- Pulmonary causes of dyspnea: COPD, pulmonary embolism, pneumonia
- Non-atherosclerotic vascular disease: vasculitis, fibromuscular dysplasia, vasospasm (Prinzmetal angina)
- Valvular heart disease presenting with similar symptoms but a different primary mechanism
- Cardiomyopathies (dilated, hypertrophic) that cause heart failure without significant coronary disease
Management
Management rests on two pillars: aggressive risk factor modification and targeted pharmacologic/procedural therapy for established disease. Guidelines from the ACC/AHA and European Society of Cardiology (ESC) are broadly concordant, with minor differences in LDL targets and risk thresholds for statin initiation.
Lifestyle and risk factor control
- Smoking cessation
- Mediterranean-style or DASH diet, reduced sodium intake
- Regular aerobic exercise
- Weight management
- Glycemic control in diabetics
Pharmacologic therapy
- Statins for LDL lowering, foundational in both primary and secondary prevention
- Antihypertensives (ACE inhibitors/ARBs, calcium channel blockers, thiazides, beta-blockers) tailored to comorbidities
- Antiplatelet therapy (aspirin, P2Y12 inhibitors) in established atherosclerotic disease
- Beta-blockers and ACE inhibitors/ARBs in post-MI patients and heart failure
- SGLT2 inhibitors and GLP-1 receptor agonists, now recommended in diabetic and high-risk patients for cardiovascular benefit independent of glycemic effect
Procedural and surgical options
- Percutaneous coronary intervention for significant coronary stenosis or acute coronary syndrome
- Coronary artery bypass grafting for multivessel or left main disease
- Carotid endarterectomy or stenting for symptomatic carotid stenosis
- Revascularization for critical limb ischemia
Primary prevention (treating risk factors before any event) and secondary prevention (preventing recurrence after a diagnosed event) both follow this same framework, with secondary prevention typically using more intensive targets.
Complications and prognosis
- Myocardial infarction, with risk of cardiogenic shock, arrhythmia, and mechanical complications (papillary muscle rupture, ventricular septal defect)
- Heart failure from ischemic cardiomyopathy or chronic pressure/volume overload
- Stroke, either ischemic (embolic or thrombotic) or secondary to hypertensive hemorrhage
- Peripheral artery disease progressing to critical limb ischemia and amputation
- Sudden cardiac death from ventricular arrhythmia
Prognosis has improved substantially with modern revascularization and pharmacotherapy, but CVD remains the leading global cause of death. Prognosis is best when risk factors are controlled early and consistently; recurrent events are common without adherence to secondary prevention therapy.
Risk factors "ABCDE": Age/family history, Blood pressure, Cholesterol/Cigarettes, Diabetes, Excess weight (obesity/sedentary lifestyle)
Practice questions
1. A 58-year-old man with a 30-pack-year smoking history and type 2 diabetes presents with exertional chest tightness relieved by rest. Coronary angiography shows a 70% stenosis of the left anterior descending artery with a thick fibrous cap and no thrombus. Which of the following best describes this lesion?
2. A 65-year-old woman with hypertension and hyperlipidemia is started on a statin after calculation of her 10-year ASCVD risk. Which cellular event best explains the earliest step in the atherosclerotic process that this therapy targets?
3. A 70-year-old man with known peripheral artery disease and prior myocardial infarction is seen for secondary prevention. In addition to statin therapy and antiplatelet agents, which additional drug class has demonstrated cardiovascular benefit in high-risk patients independent of glycemic control, even in those without diabetes?
Frequently asked questions
What causes cardiovascular disease?
Cardiovascular disease is most commonly caused by atherosclerosis, a buildup of lipid-laden plaque within artery walls driven by endothelial injury, high LDL cholesterol, hypertension, smoking, and diabetes. Chronic inflammation drives plaque growth, and rupture of an unstable plaque with superimposed thrombosis triggers acute events like heart attack or stroke. Non-atherosclerotic causes include congenital heart defects, cardiomyopathies, and valvular disease.
What are the first symptoms of cardiovascular disease?
Early cardiovascular disease is often silent, with no symptoms despite ongoing plaque buildup. When symptoms appear, they commonly include exertional chest discomfort, shortness of breath with activity, fatigue, or leg pain with walking (claudication). Many people first discover risk factors like high blood pressure or cholesterol during routine screening, before any symptoms develop.
How is cardiovascular disease diagnosed?
Diagnosis starts with risk factor assessment, including blood pressure, lipid panel, and blood glucose, combined with a calculated 10-year risk score. Depending on suspected location, further testing may include ECG, stress testing, coronary CT angiography, carotid ultrasound, ankle-brachial index, or echocardiography. Acute presentations are evaluated with troponin levels, ECG, and urgent imaging.
Is cardiovascular disease curable?
Cardiovascular disease is generally not curable but is highly manageable and often preventable. Lifestyle changes, medications like statins and antihypertensives, and procedures such as stenting or bypass surgery can control symptoms, slow progression, and significantly reduce the risk of heart attack, stroke, and death. Early, consistent risk factor control offers the best long-term outcomes.
Cardiovascular disease vs coronary artery disease — what is the difference?
Cardiovascular disease is a broad umbrella term covering any disease of the heart and blood vessels, including coronary artery disease, stroke, peripheral artery disease, and heart failure. Coronary artery disease specifically refers to atherosclerosis of the coronary arteries supplying the heart muscle. In other words, coronary artery disease is one major subtype within the larger category of cardiovascular disease.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: I51.6
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.